Overview of Selzentry
Selzentry, also known by its generic name maraviroc, is a chemokine receptor antagonist used in the treatment of HIV infection. It belongs to the class of entry inhibitors, specifically targeting the CCR5 co-receptor to prevent the virus from entering host cells[2].
Market Size and Growth
The global HIV drugs market, within which Selzentry is a key player, is projected to grow significantly over the coming years. The market was valued at $32.8 billion in 2022 and is expected to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032[1].
Regional Market Performance
North America currently holds the largest market share for HIV drugs, including Selzentry, due to robust healthcare infrastructure, strong presence of key players, and high healthcare expenditure. However, the Asia-Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by increasing cases of HIV, high population bases, and rising public-private investments in healthcare[1].
Pricing and Cost Considerations
The pricing of Selzentry varies based on the formulation and quantity.
- Oral Liquid: A supply of 230 milliliters of Selzentry oral liquid (20 mg/mL) costs around $941[2].
- Oral Tablets:
- 25 mg: 120 tablets cost from $616.77, with a per-unit price of $5.14[2].
- 75 mg: 120 tablets cost from $1,831.28, with a per-unit price of $15.26[2].
- 150 mg: 60 tablets cost from $1,831.28, with a per-unit price of $30.52[2].
- 300 mg: 60 tablets cost from $1,831.28, with a per-unit price of $30.52[2].
Generic Availability and Impact on Pricing
A generic version of maraviroc is available, which can significantly impact the pricing. For instance, the generic version of maraviroc (150 mg tablet) costs around $1,141 for 60 tablets, compared to the branded Selzentry which costs $1,730 for the same quantity[5].
Market Trends and Drivers
The demand for Selzentry and other HIV drugs is driven by several factors:
- Increasing Cases of HIV: According to UNAIDS, 39 million people globally were living with HIV in 2022, and 1.3 million people became newly infected with HIV in the same year[1].
- Advancements in HIV Drugs: Continuous research and development in HIV therapeutics, including the introduction of new drugs and formulations, drive market growth[1].
- Government Initiatives and Awareness: Increased initiatives by government associations to raise awareness about HIV diagnosis and management also contribute to the market's expansion[1].
Competitive Analysis
Selzentry competes in a market dominated by several key players, including Gilead Sciences, Inc., GlaxoSmithKline plc (ViiV Healthcare), Johnson & Johnson, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd. The competitive landscape is characterized by a focus on research and development, patient advocacy, and strategic market expansion, particularly in emerging economies[1].
Price Projections
Given the overall growth of the HIV drugs market and the specific trends affecting Selzentry, here are some price projection insights:
- Short-Term: Prices are likely to remain stable or see a slight increase due to the ongoing demand and the presence of a sophisticated reimbursement structure that helps reduce expenditure levels[1].
- Long-Term: As generic versions become more prevalent and competition increases, prices may see a downward trend. However, advancements in drug formulations and the introduction of new therapies could maintain or even increase prices if they offer significant clinical benefits[5].
Key Takeaways
- Market Growth: The HIV drugs market, including Selzentry, is expected to grow at a CAGR of 4.5% from 2023 to 2032.
- Pricing: Current prices range from $616.77 for 120 tablets of the 25 mg formulation to $1,831.28 for 60 tablets of the 150 mg and 300 mg formulations.
- Generic Impact: The availability of generic maraviroc is expected to influence pricing, potentially reducing costs for patients.
- Regional Trends: Asia-Pacific is anticipated to show the highest growth rate, driven by population and healthcare investment factors.
FAQs
Q: What is the current market size of the HIV drugs market?
A: The global HIV drugs market was valued at $32.8 billion in 2022[1].
Q: What is the projected growth rate of the HIV drugs market?
A: The market is expected to grow at a CAGR of 4.5% from 2023 to 2032[1].
Q: How much does Selzentry cost?
A: The cost of Selzentry varies by formulation, but for example, 120 tablets of the 25 mg oral tablet cost from $616.77[2].
Q: Is a generic version of Selzentry available?
A: Yes, a generic version of maraviroc is available, which can be more cost-effective[5].
Q: Which region is expected to show the highest growth in the HIV drugs market?
A: The Asia-Pacific region is anticipated to show the highest growth rate during the forecast period[1].
Sources
- Allied Market Research: HIV Drugs Market Size, Share and Growth Analysis | Report, 2032
- Drugs.com: Selzentry Prices, Coupons, Copay Cards & Patient Assistance
- Biospace: Schizophrenia Market Size to Reach USD 15,236.9 Million by 2034 ...
- GlobeNewswire: Outlook on the HIV Drugs Global Market to 2027 - Opportunity Analysis and Industry Forecast
- Clinical Info HIV.gov: Cost Considerations and Antiretroviral Therapy - Adult and Adolescent ARV Guidelines
